FilingReader Intelligence
Salubris reports H1 growth, invests in biotech fund
August 19, 2025 at 05:28 PM UTC•By FilingReader AI
Shenzhen Salubris Pharmaceuticals reported 4.32% revenue growth to 2.13 billion yuan and 6.10% net profit rise to 365.08 million yuan in H1 2025.
The company will invest up to 50 million yuan in the Shenzhen Songhe Cell and Gene Industry Private Equity Investment Fund Partnership, aligning with its advanced biotechnology strategy.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
2025 semi-annual reportAugust 19, 2025 at 08:00 AM UTC
Announcement regarding participation in the subscription for shares in an equity investment fundAugust 19, 2025 at 08:00 AM UTC
Special report on the deposit and use of raised funds for the first half of 2025August 19, 2025 at 08:00 AM UTC
Announcement of resolutions from the 13th meeting of the sixth board of directorsAugust 19, 2025 at 08:00 AM UTC
Summary table of semi-annual non-operating fund occupation and other related party fund transactionsAugust 19, 2025 at 08:00 AM UTC
2025 semi-annual report summaryAugust 19, 2025 at 08:00 AM UTC
SZSE:002294•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Shenzhen Salubris Pharmaceuticals publishes news
Free account required • Unsubscribe anytime